leisure time -WSS

leisure time

author：leisure time 2025-08-28 08:40:22 - browse：269

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： AI for drug discovery: Experts on separating hype from reality

focus

hotspot

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

Welsh Carson private equity firm escapes from FTC antitrust case

Health AI adoption puts security, privacy startups on investors' radar

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Warren pushes Witty on UnitedHealth's control over physicians

Asbestos, a deadly carcinogen, banned by EPA

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Is it ever OK for doctors to lie to their patients?

How one medical school became remarkably diverse

Asbestos, a deadly carcinogen, banned by EPA

Anesthesiologist group: stop taking Ozempic before surgery

Black vets could get higher VA benefits if race not used in lung test

Apple is now the first public company to be valued at $3 trillion

Brain technologies pose threats that are all too real, experts warn

Guidelines to prevent youth baseball injuries need more muscle

AI for drug discovery: Experts on separating hype from reality

Wikipedia

Baby aspirin cuts fat buildup in liver disease patients, in small study

As health system earnings go up, health insurance stocks go down

Stop the failed accountable care organization experiment

Empower primary care with adequate payments and technology

Asbestos, a deadly carcinogen, banned by EPA

U.K. researchers warn about biases in medical devices, algorithms

explore

focus

hotspot

entertainment